Accessibility navigation


Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's disease.

Kluss, J. H. ORCID: https://orcid.org/0000-0002-6262-6661, Lewis, P. A. ORCID: https://orcid.org/0000-0003-4537-0489 and Greggio, E. ORCID: https://orcid.org/0000-0002-8172-3598 (2022) Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's disease. Expert Opinion on Therapeutic Targets. ISSN 1744-7631

[img]
Preview
Text (Open Access) - Published Version
· Available under License Creative Commons Attribution Non-commercial No Derivatives.
· Please see our End User Agreement before downloading.

3MB

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.1080/14728222.2022.2082937

Abstract/Summary

In this review, we will provide an update on the current status of drugs and other technologies that have emerged in recent years and provide an overview of their efficacy in ameliorating LRRK2 kinase activity and overall safety in animal models and humans. The growth of both target discovery and innovative drug design has sparked a lot of excitement for the future of how we treat Parkinson's disease. Given the immense focus on LRRK2 as a therapeutic target, it is expected within the next decade to determine its therapeutic properties, or lack thereof, for PD.

Item Type:Article
Divisions:Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
ID Code:105687
Uncontrolled Keywords:LRRK2, Parkinson’s disease, kinase inhibition, Leucine-rich repeat kinase 2
Publisher:Taylor & Francis

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation